# Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma

> **NCT04682158** · PHASE2 · RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 106 (estimated)

## Conditions studied

- Esophageal Adenocarcinoma

## Interventions

- **DRUG:** Carboplatin
- **RADIATION:** 3 Dimensional Conformal Radiation Therapy
- **DRUG:** Propranolol
- **RADIATION:** Intensity Modulated Radiation Therapy
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04682158
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-01
- **Primary completion:** 2029-04-01
- **Final completion:** 2029-04-01
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2026-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04682158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04682158, "Propranolol With Standard Chemoradiation for Esophageal Adenocarcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04682158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*